PDEX
PRO DEX INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$57.70
−0.96%Year over year
Reported trailing growth
- Revenue
- +16.4%
- EBITDA
- +41.3%
- EBIT
- +21.5%
- EPS
- +52.9%
- Free cash flow
- +335.4%
- Operating cash flow
- +530.6%
Forward estimates
Based on analyst estimates
- Revenue
- +7.8%
- EBITDA
- -19.3%
- EPS
- -24.6%
Three-year CAGR
- Revenue
- +18.9%
- EBITDA
- +10.0%
- EBIT
- +31.1%
- Net income
- +24.5%
- EPS
- +28.9%
- Free cash flow
- +14.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026